Join the Newsletter
Hair loss treatments attract strong opinions. Some people are convinced “nothing works”; others believe a single product or procedure can fully restore their hair. This article reviews common myths about treatments – from minoxidil and 5α-reductase inhibitors to low-dose oral minoxidil, PRP, laser devices and surgery – and summarises what reasonably good evidence actually shows.
![[headshot]](https://cdn.prod.website-files.com/68207da82e5b8c350c67932f/68c6a7436a552c0fe87a4da7_Screenshot%202024-11-27%20at%2011.38.11.png)
Myth in short
It is common to see blanket statements that all treatments are marketing, and that androgenetic alopecia (AGA) or female pattern hair loss (FPHL) cannot be influenced.
What the evidence shows
Network meta-analyses and guidelines conclude that minoxidil and finasteride/dutasteride (in men) are effective disease-modifying treatments for AGA. They do not cure AGA, but they do change its trajectory.
Balanced view
It is inaccurate to say “nothing works”. Evidence shows that approved drugs and some adjunctive treatments slow progression and, in many patients, partially reverse miniaturisation. Expectations should be around stabilisation and modest regrowth, not complete restoration.
Myth in short
In contrast, some narratives imply a sensationalist view that these drugs reliably restore a full head of hair. There are some wild success stories with striking before and after photos online from just medical therapy alone.
What the evidence shows
Even in favourable conditions, there is a ceiling: follicles that have been miniaturised for a long time may not fully recover, and areas that are shiny and essentially bald may have few or no follicles left to stimulate.
Combination therapy can enhance efficacy: a recent meta-analysis of 7 RCTs (396 men) found that a topical minoxidil–finasteride combination produced greater improvements in hair density and diameter, as well as better global assessments, than minoxidil alone.
Balanced view
Minoxidil and finasteride/dutasteride are powerful tools, but they are not magic. In realistic terms, “success” usually means slowing or halting further loss and achieving a noticeable but partial improvement, particularly when treatment is started early. This is the expectation that should be set for most.
A common and emotionally charged claim online is that finasteride or dutasteride will shut down masculinity, permanently damage libido or erections, or effectively cause chemical castration.
A large systematic review and meta-analysis of 15 randomised trials (4,495 men) found:
When broken down by drug:
Most reported effects were mild to moderate, and in long-term extension studies they tended to occur early (often within the first year) and became less common over time. Discontinuation rates due to sexual side-effects were low and similar to placebo.
Finasteride and dutasteride reduce dihydrotestosterone (DHT), not testosterone itself. Serum testosterone levels typically remain within the normal range, and in some men rise slightly due to reduced conversion to DHT. Sexual function is regulated by multiple pathways (testosterone, oestrogens, neural and vascular factors), not DHT alone.
Regarding fertility, there is no credible evidence that finasteride or dutasteride cause permanent infertility or render men unable to father children in the absence of other contributing factors. A common pragmatic approach is to pause treatment if concerns arise during active attempts to conceive.
Finasteride and dutasteride do not chemically castrate men. They modestly increase the risk of sexual side-effects in a small proportion of users, and those effects are genuine for the men who experience them. However, the absolute risk is low, testosterone production is preserved, and fertility is generally unaffected and reversible. Framing these drugs as castrating agents misrepresents both their pharmacology and the clinical evidence, and risks replacing informed consent with fear into trying untested products.
Myth in short
The idea here is that these treatments create dependence, and that stopping them makes hair fall out worse than before, meaning you're better off avoiding them if you think you cannot commit to it for life.
What the evidence shows is that AGA and FPHL are chronic, progressive conditions. Left alone, they tend to worsen over time.
Minoxidil and 5𝝰-reductase inhibitors maintain follicles in a more favourable state while they are used. If they are stopped:
This is analogous to blood pressure or cholesterol treatment: stopping treatment does not mean the drug has “damaged” the underlying system; rather, it indicates that the underlying biology is no longer being modulated.
There is no evidence that minoxidil or finasteride cause a rebound loss beyond natural history when used appropriately and discontinued.
Balanced view
These drugs are maintenance-dependent, not addictive. As long as you want to preserve their benefits, you need to continue them. If you stop, the hair gradually returns to its untreated state. Deciding whether long-term treatment aligns with your priorities is a personal judgement.
Myth in short
Low-dose oral minoxidil (LDOM) is increasingly discussed; some sources portray it as “a game changer”, others as inherently risky. Many forget it has been licensed for severe hypertension for decades, in much higher doses.
What the evidence shows
LDOM remains off-label and requires medical screening (particularly for cardiovascular disease and blood pressure issues), as well as cautious dosing and ongoing monitoring.
Balanced view
At low doses in carefully selected patients, oral minoxidil appears reasonably effective and generally well tolerated, but it is not benign and is not a first-line choice for everyone. It should be considered and monitored like any other systemic drug (by a professional), particularly if you have a past medical history or take regular medications already.
Myth in short
Regenerative therapies are often described as if they have replaced pharmacological and surgical treatments.
What the evidence shows
Platelet-rich plasma (PRP):
Stem cell-related treatments (e.g. adipose-derived stem cell conditioned media, micrografts, exosomes):
None of these modalities have been shown in high-quality trials to restore hair to pre-morbid levels in advanced AGA consistently. They are best thought of as adjunctive treatments that may enhance density, especially in mild-to-moderate disease, or in combination with other therapies.
Balanced view
PRP and emerging cell-based treatments are useful additions to the toolbox, with evidence for modest improvements in selected patients. They are not proven cures, and expectations should be set accordingly – particularly when costs are high and repeated sessions are needed.
Myth in short
Low-level laser/light therapy (LLLT) devices are sometimes dismissed as entirely ineffective or, conversely, promoted as standalone cures.
What the evidence shows
Studies comparing LLLT combined with minoxidil versus minoxidil alone suggest an additive benefit for some patients. However:
Balanced view
LLLT is not a scam; it has evidence for modest efficacy in AGA/FPHL when used appropriately. It is a supportive modality rather than a replacement for pharmacologic or surgical treatment; however, it requires high consistency, which may be a burden for many, for the modest gains it may yield.
We have a separate detailed article on supplements; here, we discuss the key myth surrounding.
Myth in short
Some marketing suggests that nutraceuticals and vitamin complexes are equal to or superior to minoxidil and finasteride. Some influencers purport vitamin D supplementation as a cure.
What the evidence shows
Balanced view
Supplements have a role in correcting deficiencies and supporting hair in certain contexts, but they are not on the same footing as pharmacologic treatments for patterned hair loss, where patient's serum vitamin levels are typically normal.
Myth in short
Surgery is sometimes seen as a definitive fix that ends the hair loss story.
What the evidence shows
Studies of post-transplant self-management show that adherence to medical therapy and aftercare improves satisfaction and long-term appearance.
Balanced view
A well-planned transplant can significantly improve coverage and framing, but it does not “reset” genetics. Continuing evidence-based medical therapy afterwards is considered best practice, and future progression of hair loss elsewhere remains possible.
A more evidence-aligned framing of treatments might look like this:
Approaching treatments with this pattern in mind, rather than hoping for a single cure or rejecting everything as futile, enables rational, personalised decisions with better outcomes.
